Sarwar et al. [11
] reported in a recent meta-analysis that triglyceride levels are an independent cardiovascular risk factor even when adjusted for HDL-C. For mild to moderate HTG, consideration should be given to familial dyslipidemias that include familial combined hyperlipidemia, familial HTG, and familial dysbetalipoproteinemia (type III dyslipidemia). Familiar HTG is an autosomal-dominant disorder with elevated levels of VLDL-cholesterol (VLDL-C) mainly due to large VLDL particles [12
••]. These patients generally have normal levels of LDL-C and apo B levels and can have low levels of HDL-C [12
••]. They do not appear to have an increased risk for CVD unless they also have enough features to define them as having the metabolic syndrome. Familial combined hyperlipidemia is also an autosomal-dominant disorder with an overproduction of apo B-100 particles [13
••]. In this disorder, there is a family history of premature heart disease; and family members can have elevated levels of cholesterol, triglycerides, or combined hyperlipidemia. These patients are at increased risk for premature coronary artery disease (CAD) and have elevated apo B levels [13
••]. Invariably these patients have a preponderance of small dense LDL particles. The third familial disorder that can result in mild to moderate HTG is type III dyslipidemia or dysbetalipoproteinemia. These patients usually are homozygous for apo E2; its frequency in the population is approximately 1% and can be easily determined by genotyping for apoprotein E. However, to manifest type III hyperlipoproteinemia, a second hit is required; this usually is a secondary factor such as diabetes, obesity, hypothyroidism, or renal disease. They classically present with cholesterol and triglyceride levels in the same order of magnitude between 200 to 600 mg/dL. Clinically, these patients present with tuberoeruptive xanthomas and xanthomas in palm creases (xanthoma palmaris striata), and can manifest features of CAD and peripheral arterial disease. They have elevated levels of VLDL-C and intermediate-density lipoprotein cholesterol and low levels of HDL-C and LDL-C by β quantification. On electrophoresis, they have a broad β band spanning the pre-β/β area. The diagnostic test for type III hyperlipoproteinemia is ultracentrifugation and reporting the VLDL-C/total triglycerides ratio. In patients with type III hyperlipoproteinemia, a ratio of greater than 0.3 is diagnostic and usually means that there is β-VLDL present. Table depicts laboratory tests that can be useful in the workup of patients with HTG.
Investigation of hypertriglyceridemia
With respect to the management of mild to moderate HTG, therapeutic lifestyle change is a primary treatment, with a focus on reduction of saturated fat, cholesterol, trans fat, refined carbohydrates, and encouragement of a high-fiber diet with at least 30–40 g/d. Cigarette use is another modifiable risk factor that can be part of life-style changes. Smoking cessation results in an improved lipid profile despite the weight gain that often occurs after one stops smoking [13
••]. In addition, statin therapy will be the treatment of choice to achieve levels of LDL-C less than 100 mg/dL and non-HDL-C less than 130 mg/dL in patients with diabetes without CVD [14
]. In a diabetic patient with CVD, the LDL-C goal is less than 70 mg/dL and the non-HDL-C goal is less than 100 mg/dL. The non-HDL-C goal should also be a secondary target, especially if the triglyceride levels are greater than 150 mg/dL [14
]. In achieving these goals, in addition to statin therapy, one has to consider combination therapy with niacin, fibrates, or omega-3 fatty acids.
Regarding therapeutic lifestyle change and HTG, body weight control is critical, regular physical activity should be encouraged, alcohol intake should be restricted, and avoidance of high-carbohydrate diets (especially with refined carbohydrates) should be encouraged. The evidence base for niacin therapy in diabetic patients on statins is scant. However, niacin therapy has been known to reduce LDL-C, non-HDL-C, and triglycerides, and increase HDL-C. In the CDP, niacin therapy resulted in reduction of cardiovascular events (CVEs) and mortality in patients with CAD [15
]. Side effects of niacin therapy include flushing, abnormal liver function tests, hyperglycemia, and hyperuricemia. Generally, niacin therapy should be combined with statin therapy in patients with mild to moderate HTG, if the hemoglobin A1c
is around 7% (ie, good diabetes control). In the HATS study, there was a clear benefit of the combination of simvastatin/niacin therapy versus placebo on both coronary angiographic progression and CVEs. However, only 16% of the 160 patients with coronary heart disease (CHD) were diabetic [16
]. In the ARBITER 3 study, patients were followed up for 24 months and carotid intima-media thickness (IMT) regression was evident with niacin therapy. The subcohort with diabetes or the metabolic syndrome included 62 patients [17
]. In the ARBITER 6-HALTS study, which comprised 208 patients with CHD or CHD risk equivalent, all of whom were on statin therapy with LDL levels less than 100 mg/dL and HDL-C levels below 50 and 55 mg/dL in men and women, respectively, 40% of the patients on ezetimibe and 32% on niacin were diabetic [18
]. Niacin therapy resulted in significant reduction in mean and maximum carotid IMT over 14 months and decrease in major CVEs. The effect of niacin therapy on mean carotid IMT was consistent across prespecified subgroups including presence and absence of diabetes [18
]. Studies that are in progress that include diabetic patients are the AIM HIGH study with a comparison of niacin/simvastatin versus simvastatin therapy on CVD, and also the HPS2-THRIVE study in which niacin combined with laropiprant (D2 antagonist) plus statin therapy is being examined. Because both of these studies include diabetic patients, they will better inform us about niacin therapy in addition to statins in patients with mild to moderate hypertriglyceredemia to reduce the residual risk that is manifest even in statin-treated diabetics. Although the sample sizes of diabetic patients are small in the studies summarized above, the collective results are promising.
The best data about peroxisome proliferator-activated receptor-α agonist fibrate therapy (fibrate therapy in patients with diabetes) is the VA-HIT study. In this study, they showed that in the 627 diabetic patients there was 24% reduction in the expanded end point of death from CHD, nonfatal myocardial infarction (MI), and confirmed stroke (P
0.05) in the diabetic group who received gemfibrozil compared with placebo [19
]. In a subsequent report, in which the diagnosis of diabetes was modified to include the new criteria of fasting plasma glucose ≥ 126 mg/dL, the total cohort of diabetic patients was increased to 769 and there was a 32% risk reduction of the composite end point of CHD death, stroke, or MI (P
]. This decrease was largely due to a reduction in CHD death. In the DAIS, 418 T2DM patients were randomized to fenofibrate (200 mg/d) or placebo for 3 years [21
]. There were significant reductions in LDL-C, triglycerides, and increases in HDL-C. In the group that received fenofibrate, there was significantly less coronary angiographic progression in minimum lumen diameter and percent diameter stenosis. There was no significant effect on average of mean segment diameter. Also, there was a decrease in the incidence of microalbuminuria. In the FIELD study, 9725 T2DM patients not on statin therapy, 2131 with previous CVD with total cholesterol between 116 to 251 mg/dL, and triglyceride levels between 88.6 to 443 mg/dL were studied. The primary outcome in the study was CHD death and nonfatal MI. During the trial 17% of the placebo and 8% of the fenofibrate group started other lipid therapy, which was mainly statins. At study end, there was a 22% reduction in triglycerides, 6% decrease in LDL-C, and 1% increase in HDL-C [22
]. There was a nonsignificant 11% reduction in the primary end point (P
0.16), 24% reduction in nonfatal MI (P
0.01), nonsignificant increase in CHD mortality of 19% (P
0.22), and total CVE (comprising CVD death, MI, stroke, and revascularization) was reduced by 11% (P
0.035). Other significant effects in the study included reduction in albuminuria and retinopathy needing laser therapy. Also, there was significant increased risk of pancreatitis and pulmonary embolism, and increase in both homocysteine and creatinine levels.
With regard to the fibrate therapy, side effects include gastrointestinal symptoms. Although there is an increased excretion of biliary cholesterol, there does not seem to be any increased risk of gallstones with fenofibrate therapy. Both fenofibrate and gemfibrozil displace warfarin from protein binding, so the warfarin dose has to be titrated in these patients to achieve their goal International Normalized Ratio. There also appeared to be an increase in both creatinine and homocysteine levels with fenofibrate therapy. Furthermore, the combination of statin and fibrate, especially gemfibrozil, in patients with renal failure, cholestasis, hypothyroidism, and aging increases the risk of rhabdomyolysis. It appears that gemfibrozil interferes with statin glucuronidation.
The final study is the ACCORD study (lipid arm), which was published recently [23
••]. In this study, 5518 patients on fenofibrate and simvastatin were compared to simvastatin therapy and they were followed up for a mean duration of 4.3 years. There was no significant benefit on the primary end point, which was a composite of nonfatal MI, nonfatal stroke, and CVD death or any of the prespecified secondary end points [23
••]. Also, in the prespecified subgroup analyses, there was a benefit for men and possible harm for women. A trend to benefit was evident (P
0.057) in patients with both high triglyceride levels (≥204 mg/dL) and low levels of HDL-C (<34 mg/dL). As in the FIELD and DAIS studies, there was a lower incidence of both microalbuminuria and macroalbuminuria in the fenobibrate group despite a significant increase in creatinine and decrease in glomerular filtration rate. Of interest,
the group receiving a combination of fenofibrate and simvastatin did not have a statistically significant increase in myositis or rhabdomyolysis in the ACCORD trial [23
••]. The investigators stated in their conclusion that their results do not support the routine use of fenofibrate in combination with simvastatin to reduce CVEs in the majority of patients with diabetes.